Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
YTS-109 by Bristar Immunotech Biotechnology for Dermatomyositis: Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Dermatomyositis. According to GlobalData, Phase...
YTS-109 by Bristar Immunotech Biotechnology for Polymyositis: Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis. According to GlobalData, Phase...
YTS-109 by Bristar Immunotech Biotechnology for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA...
YTE-001 by Bristar Immunotech Biotechnology for Hemophagocytic Lymphohistiocytosis: Likelihood of Approval
YTE-001 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData,...
CD19-STAR-T Cells by Bristar Immunotech Biotechnology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
CD19-STAR-T Cells is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Acute Lymphocytic Leukemia (ALL,...